Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
about
Recommendations for nanomedicine human subjects research oversight: an evolutionary approach for an emerging fieldBuilding an ethical foundation for first-in-human nanotrialsA biological perspective on memoryRisk of surgical delivery to deep nuclei: a meta-analysisStakeholder views on participant selection for first-in-human trials in cancer nanomedicine.Efficacy and safety of mesenchymal stromal cells in preclinical models of acute lung injury: a systematic review protocol.How can institutional review boards best interpret preclinical data?Stem cell trials for cardiovascular medicine: ethical rationale.Beyond bench and bedside: disentangling the concept of translational research.Barriers to developing a valid rodent model of Alzheimer's disease: from behavioral analysis to etiological mechanismsSource memory in the rat.Zinc finger nucleases: looking toward translation.Through the fog: recent clinical trials to preserve β-cell function in type 1 diabetes.Current status of cell-mediated regenerative therapies for human spinal cord injury.Defining Nano, Nanotechnology and Nanomedicine: Why Should It Matter?How do researchers decide early clinical trials?Participant selection for preventive Regenerative Medicine trials: ethical challenges of selecting individuals at risk.Rethinking risk assessment for emerging technology first-in-human trials.Assessing risk/benefit for trials using preclinical evidence: a proposal.How to keep high-risk studies ethical: classifying candidate solutions.Ethics, error, and initial trials of efficacyResearch on HIV cure: Mapping the ethics landscape.Scientific non-publishing: the addressed, the unaddressed and the unexplored.First-In-Human Phase 1 CRISPR Gene Editing Cancer Trials: Are We Ready?Streamlining review of research involving humans: Canadian models.The structure of clinical translation: efficiency, information, and ethics.Benefit-Risk Analysis for Decision-Making: An Approach.Risk Assessment and Risk Minimization in Nanomedicine: A Need for Predictive, Alternative, and 3Rs Strategies.Nanomedicine first-in-human research: challenges for informed consentControlling Brain Cells With Light: Ethical Considerations for Optogenetic Clinical TrialsRefining Ethical Guidelines for Early Clinical Trials of Pluripotent Stem-Cell-Derived Therapeutics for Parkinson's DiseaseImproving Subject Safety in High-Risk Phase I Trials With Stem Cell-Based Candidate TherapiesThe Shared Ethical Responsibility of Medically and Non-medically Qualified Experts in Human Drug Development TeamsPerspective: Rethink the immune connection
P2860
Q26822431-9567073D-C8FD-4E25-9CDB-1E1182960726Q28396571-542F4C3C-C80B-4C66-930E-4964F8770AA4Q28588858-84B9BDA0-4914-411D-BFEA-BA5C01DE0201Q30371423-E64E6291-B7F0-4F96-97A6-EEFFAFEB1150Q30832708-EA64F560-A141-4A3B-B8D3-3E862212DF88Q33714606-7BE91C70-06AD-4280-807E-FE4C59570F03Q33851232-0A8CFE12-AFA4-40C1-980F-A0A200850E74Q34331206-55D553AA-0AD8-4403-9F11-03090D644EFFQ34947361-C1993F96-0CEA-4690-9F7C-218FB8907928Q35898532-D3196DF6-9111-4FDB-9231-F667014EEA6FQ36678053-00E985EC-54E0-46F3-A47B-E4E65A0346BFQ37982615-9C1631D6-E8A4-413A-9001-6FE3ACC7A4FCQ38012381-6BBDBAB0-D209-4F58-AB29-D9B351C82894Q38210966-F34724D0-1317-49DC-B3A5-96A4E4B84A6CQ38587494-E83F3D72-F106-4815-A2C6-12AE5ACF10C3Q38718855-2C4BDDC4-82AE-4915-B3BA-FF88A53240E6Q38967151-A3D8C8D8-0C80-4AC1-8C73-59E38E29A472Q38974025-C0F1A609-EF04-4F02-8CC6-61876792E143Q40925322-126B0765-0B9D-408F-809A-72E4DA0A25A8Q42355200-9B0D900D-15A5-4C85-82FB-CFF77FE7DF82Q42395017-65A32E14-6EA9-41EE-A93E-B28C48699083Q46049688-B2931900-8F2D-4019-8A6D-1D5D19416468Q46195514-0D17230F-EB3C-4A44-AAD4-C5E90499F4B0Q47283164-19F71EAE-447B-43CE-8A12-221BECD60760Q48036747-1DC25039-644B-471C-9714-ED0B79679B69Q48051735-50CB78DC-7330-4F08-BDF4-9B3F4BC025B4Q48770147-5F5C83B9-6FCF-478B-ABE7-206154A40452Q52584444-BBD01B90-5F3C-463C-A1CE-F56F0811DFBFQ56775615-5EBB5650-BC7E-4136-A0F4-9FA50B344EF9Q58106799-BDB141FB-446D-4EBE-A840-B24C55BE504CQ58172885-9526B335-2071-4DF3-873D-8FC69FE4029FQ58188352-7E714EB0-CD61-4B77-A849-48C244383CD4Q58657078-DFCFD683-B685-4D08-9A3B-211912AB67E4Q74441430-E09D9810-88A1-47D8-8995-C774724AA034
P2860
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
@ast
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
@en
type
label
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
@ast
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
@en
prefLabel
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
@ast
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
@en
P2860
P1433
P1476
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.
@en
P2860
P304
P356
10.1371/JOURNAL.PMED.1001010
P407
P577
2011-03-08T00:00:00Z